Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer

Regorafenib has shown significant survival benefit as a salvage therapy for colorectal cancer; however, its starting dose has been controversial in recent studies. Therefore, we conducted a prospective study on the efficacy and safety of the dose reduction of regorafenib to 120 mg. Patients received...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Takeshi, Kudo, Toshihiro, Kagawa, Yoshinori, Murata, Kohei, Ota, Hirofumi, Noura, Shingo, Hasegawa, Junichi, Tamagawa, Hiroshi, Ohta, Katsuya, Ikenaga, Masakazu, Miyazaki, Susumu, Komori, Takamichi, Uemura, Mamoru, Nishimura, Junichi, Hata, Taishi, Matsuda, Chu, Satoh, Taroh, Mizushima, Tsunekazu, Ohno, Yuko, Yamamoto, Hirofumi, Doki, Yuichiro, Eguchi, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911606/
https://www.ncbi.nlm.nih.gov/pubmed/36759648
http://dx.doi.org/10.1038/s41598-022-24057-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911606/
https://www.ncbi.nlm.nih.gov/pubmed/36759648
http://dx.doi.org/10.1038/s41598-022-24057-0

Ejemplares similares